Bladder Cancer Research
FDA Approves Nivolumab for Bladder CancerPosted: March 1, 2017
The FDA has approved nivolumab for the treatment of unresectable locally advanced or metastatic bladder cancer that worsened after treatment with platinum-based chemotherapy.
FDA Approves New Immunotherapy Drug for Bladder CancerPosted: June 7, 2016
The FDA has approved atezolizumab (Tecentriq®) for the treatment of some patients with urothelial carcinoma, the most common type of bladder cancer.
Elevated bladder cancer risk in New England and arsenic in drinking water from private wellsPosted: May 2, 2016
A new study has found that drinking water from private wells, particularly dug wells established during the first half of the 20th century, may have contributed to the elevated risk of bladder cancer that has been observed in Maine, New Hampshire, and Vermont for over 50 years.
TCGA bladder cancer study reveals potential drug targets, similarities to several cancersPosted: January 29, 2014
Investigators with TCGA have identified new potential therapeutic targets for a major form of bladder cancer, including important genes and pathways that are disrupted in the disease. They also discovered that, at the molecular level, some subtypes of bladder cancer resemble subtypes of breast, head and neck and lung cancers, suggesting similar routes of development.
NIH study suggests gene variation may shape bladder cancer treatmentPosted: December 26, 2012
Patients who have inherited a specific common genetic variant develop bladder cancer tumors that strongly express a protein known as prostate stem cell antigen (PSCA), which is also expressed in many pancreatic and prostate tumors, according to research at the National Institutes of Health.
Chemoradiation May Help Some Patients with Bladder Cancer Avoid Radical SurgeryPosted: May 14, 2012
Researchers in the United Kingdom have found that adding chemotherapy to radiation therapy as a treatment for bladder cancer may reduce the risk of a recurrence more than radiation alone, without causing a substantial increase in side effects.